share_log

Redhill Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcement ·  Jan 26 09:34
Summary by Moomoo AI
Redhill Biopharma Ltd., a foreign private issuer, has submitted a Form 6-K to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes several exhibits such as Securities Purchase Agreement, Warrant forms, and legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP. The Form 6-K filing, which is not an offer to sell or a solicitation of an offer to buy securities, has been incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3 filed with the SEC over the years. The document was signed by CEO Dror Ben-Asher, indicating compliance with the requirements of the Securities Exchange Act of 1934.
Redhill Biopharma Ltd., a foreign private issuer, has submitted a Form 6-K to the United States Securities and Exchange Commission (SEC) for January 2024. The report includes several exhibits such as Securities Purchase Agreement, Warrant forms, and legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP. The Form 6-K filing, which is not an offer to sell or a solicitation of an offer to buy securities, has been incorporated by reference into the company's various Registration Statements on Form S-8 and Form F-3 filed with the SEC over the years. The document was signed by CEO Dror Ben-Asher, indicating compliance with the requirements of the Securities Exchange Act of 1934.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more